Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, and Flexion Therapeutics, Inc. (Nasdaq: FLXN) today announced a definitive agreement pursuant to which Pacira will acquire Flexion for $8.50 per share in cash, plus one non-tradeable contingent value right (CVR) worth up to $8.00 per share in cash. Flexion is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, local non-opioid therapies for the treatment of patients with musculoskeletal conditions, including osteoarthritis (OA), postsurgical pain and low back pain.
Read the full article: Pacira BioSciences to Acquire Flexion Therapeutics //
Source: https://www.globenewswire.com/news-release/2021/10/11/2311713/29848/en/Pacira-BioSciences-to-Acquire-Flexion-Therapeutics-Further-Expanding-Leadership-Position-in-Non-Opioid-Pain-Management.html